# EDGAR Filing Document

**Accession Number:** 0001639691
**File Stem:** 0001639691-23-000025
**Filing Date:** 2023-3
**Character Count:** 5743
**Document Hash:** f0f373b56535e70ed77d512f081a1106
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001639691-23-000025.hdr.sgml**: 20230324

**ACCESSION NUMBER**: 0001639691-23-000025

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230322

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230324

**DATE AS OF CHANGE**: 20230324

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LivaNova PLC
- **CENTRAL INDEX KEY:** 0001639691
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **IRS NUMBER:** 981268150
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37599
- **FILM NUMBER:** 23757754

**BUSINESS ADDRESS:**
- **STREET 1:** 20 EASTBOURNE TERRACE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W2 6LG
- **BUSINESS PHONE:** 4402033250662

**MAIL ADDRESS:**
- **STREET 1:** 20 EASTBOURNE TERRACE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W2 6LG

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sand Holdco Plc
- **DATE OF NAME CHANGE:** 20150420

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sand Holdco Ltd
- **DATE OF NAME CHANGE:** 20150415

?xml version="1.0" ? livn-20230322

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 22, 2023

![livn-20230322_g1.jpg](livn-20230322_g1.jpg)

**LivaNova PLC**

(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **England and Wales** | **001-37599** | **98-1268150** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission <br>File Number) | (IRS Employer <br>Identification No.) |

---

**20 Eastbourne Terrace** 

**London, W2 6LG** 

**United Kingdom** 

(Address of Principal Executive Offices)

**+44 20 33250660** 

(Registrant's Telephone Number, Including Area Code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name on each exchange on which registered |
| Ordinary Shares - £1.00 par value per share | LIVN | NASDAQ Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 ☐

------

**Item 7.01 Regulation FD Disclosure**

On March 22, 2023, LivaNova PLC (the "Company") learned that the independent Statistical Analysis Committee advised that trial enrollment in the Company's RECOVER difficult-to-treat depression trial should continue on from 475 to 500 unipolar patients, in line with the protocol. As has been previously discussed, the study was designed with frequent interim analyses, which occur every 25 patients. The interim analysis assesses if predictive probability of success has been reached for the unipolar cohort of the study, at which point the randomized controlled trial enrollment will cease.

On March 23, 2023, LivaNova randomized the 500<sup>th</sup> unipolar patient into the trial. Upon receipt of the 12-month follow-up data for all 500 patients, the Company will conduct a final analysis for the unipolar cohort, culminating in a publication on the study results for that cohort.

The information furnished pursuant to this Current Report on Form 8-K shall not be considered "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth by specific reference in such filing that such information is to be considered "filed" or incorporated by reference therein.

**Item 9.01 Financial Statements and Exhibits**

(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.

---

| | |
|:---|:---|
| **<u>Exhibit</u>** | **<u>Description</u>** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| | LivaNova PLC |
| Date: March 23, 2023 | By: <u>/s/ Michael Hutchinson</u>  |
|  | Name: Michael Hutchinson |
|  | Title: Senior Vice President & Chief Legal Officer |

---